Search research articles
Contact Us
Filters
Showing results (161-170 of 191) with videos related to
Page
of 20
Sort By:
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Blood Advances
|
April 6, 2026
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy
Sigrun Einarsdottir, Teng Fei, Katina H Singh, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Cancer Discovery
|
November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
Alice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Daniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 191) with videos related to
Sort By:
Page
of 20
Liver Cancer
|
December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
Petros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Blood Advances
|
April 6, 2026
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy
Sigrun Einarsdottir, Teng Fei, Katina H Singh, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2019
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study
Michael S Khodadoust, Alain H Rook, Pierluigi Porcu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Cancer Discovery
|
November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Kenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
Alice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Daniel M Girardi, Scot A Niglio, Amir Mortazavi, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Page
of 20